Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of treatment options that target and treat diseases affecting the central nervous system. Its product candidates include Oliceridine injection, a G protein biased mu-opioid receptor (MOR) ligand that has completed Phase III clinical trials for the management of moderate-to-severe acute pain where intravenous administration is warranted; TRV250, a G protein biased delta- opioid receptor ligand, which is in Phase I clinical study for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR that has completed Phase I clinical study for the treatment of moderate-to-severe acute and chronic pain; TRV027 for the treatment of acute heart failure; and TRV045, a novel S1P modulator for managing chronic pain.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone610-354-8840
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$5.73 million
Profitability
Miscellaneous
Employees29
Next Earnings Date11/14/2019 (Estimated)
OptionableOptionable
Trevena (NASDAQ:TRVN) Frequently Asked Questions
What is Trevena's stock symbol?
Trevena trades on the NASDAQ under the ticker symbol "TRVN."
How were Trevena's earnings last quarter?
Trevena Inc (NASDAQ:TRVN) posted its earnings results on Wednesday, August, 7th. The biopharmaceutical company reported ($0.05) EPS for the quarter, beating the Zacks' consensus estimate of ($0.10) by $0.05. View Trevena's Earnings History.
When is Trevena's next earnings date?
What price target have analysts set for TRVN?
4 Wall Street analysts have issued twelve-month price targets for Trevena's shares. Their forecasts range from $1.00 to $15.00. On average, they anticipate Trevena's share price to reach $6.6667 in the next year. This suggests a possible upside of 573.4% from the stock's current price. View Analyst Price Targets for Trevena.
What is the consensus analysts' recommendation for Trevena?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Trevena in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Trevena.
What are Wall Street analysts saying about Trevena stock?
Here are some recent quotes from research analysts about Trevena stock:
- 1. According to Zacks Investment Research, "Trevena, Inc. is a biopharmaceutical company. It focuses on discovering and developing therapeutics for G protein coupled receptors. The Company's product pipeline includes TRV027, TRV130, TRV734 and Delta opioid biased ligand which are in different clinical phases. Trevena, Inc. is based in King of Prussia, Pennsylvania. " (8/13/2019)
- 2. HC Wainwright analysts commented, "Our $3.50 price target for Trevena is based on our sum-of-the-parts NPV valuation based on each of the company’s pipeline assets. Our DCF model utilizes a discount rate of 11.5% based on the company’s WACC (Beta of 1.5, equity risk premium of 6.7%). We adjust each indication for probability of success with 3 program has been successful, and we’re confident on the outcome of the cardiac safety study; TRV-250 at 15%; and TRV-045 at 7%. We don’t include TRV-734 in our valuation for the time being, although would look to add it to our valuation model as we gain additional insight. We apply terminal decline rates of 10% for each asset. We assume a 24% tax rate." (5/31/2019)
Has Trevena been receiving favorable news coverage?
News headlines about TRVN stock have trended negative recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Trevena earned a media sentiment score of -2.9 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the next several days. View News Stories for Trevena.
Who are some of Trevena's key competitors?
Some companies that are related to Trevena include Prothena (PRTA), Theratechnologies (THERF), Forty Seven (FTSV), Ardelyx (ARDX), Kindred Biosciences (KIN), Atreca (BCEL), OptiNose (OPTN), Albireo Pharma (ALBO), Avid Bioservices (CDMO), Minerva Neurosciences (NERV), BIOFRONTERA AG/ADR (BFRA), Clovis Oncology (CLVS), OvaScience (OVAS), Cyclerion Therapeutics (CYCN) and CV Sciences (CVSI).
What other stocks do shareholders of Trevena own?
Who are Trevena's key executives?
Trevena's management team includes the folowing people:
- Ms. Carrie L. Bourdow, Pres, CEO & Director (Age 56)
- Dr. Howard A. Rockman M.D., Scientific Founder, Consultant and Member of Scientific Advisory Board
- Mr. John P. Hamill, VP of Fin. (Age 55)
- Erin Clark, Sr. Director of Corp. Strategy & Investor Relations
- Mr. Michael Catalano, VP of Marketing
Who are Trevena's major shareholders?
Trevena's stock is owned by a number of of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (4.23%), AWM Investment Company Inc. (3.52%), BlackRock Inc. (2.86%), Renaissance Technologies LLC (2.08%), Morgan Stanley (0.57%) and JPMorgan Chase & Co. (0.28%). Company insiders that own Trevena stock include John P Hamill, Leon O Moulder Jr, Maxine Gowen and Yacoub Habib. View Institutional Ownership Trends for Trevena.
Which major investors are selling Trevena stock?
Which major investors are buying Trevena stock?
TRVN stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Morgan Stanley, Vanguard Group Inc., JPMorgan Chase & Co., Wells Fargo & Company MN, Clear Creek Financial Management LLC, Bank of New York Mellon Corp and BlackRock Inc.. Company insiders that have bought Trevena stock in the last two years include John P Hamill, Leon O Moulder Jr and Maxine Gowen. View Insider Buying and Selling for Trevena.
How do I buy shares of Trevena?
Shares of TRVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Trevena's stock price today?
One share of TRVN stock can currently be purchased for approximately $0.99.
How big of a company is Trevena?
Trevena has a market capitalization of $91.64 million and generates $5.73 million in revenue each year. The biopharmaceutical company earns $-30,780,000.00 in net income (profit) each year or ($0.42) on an earnings per share basis. Trevena employs 29 workers across the globe.View Additional Information About Trevena.
What is Trevena's official website?
How can I contact Trevena?
Trevena's mailing address is 955 Chesterbrook Boulevard Suite 110, Chesterbrook PA, 19087. The biopharmaceutical company can be reached via phone at 610-354-8840 or via email at [email protected]
MarketBeat Community Rating for Trevena (NASDAQ TRVN)
MarketBeat's community ratings are surveys of what our community members think about Trevena and other stocks. Vote "Outperform" if you believe TRVN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TRVN will underperform the S&P 500 over the long term. You may vote once every thirty days.
